trending Market Intelligence /marketintelligence/en/news-insights/trending/v2it97gO5VZ5qtwJRl9L5Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Bausch Health, Glenmark settle patent dispute over plaque psoriasis lotion

Bausch Health Cos. Inc. and Mumbai, India-based pharmaceutical company Glenmark Pharmaceuticals Ltd. agreed to settle the intellectual property lawsuit regarding Bausch's plaque psoriasis treatment Bryhali.

Under the agreement, Glenmark will have nonexclusive rights to market a royalty-free generic version of the lotion effective 2026 or earlier under certain circumstances, subject to approval from the U.S. Food and Drug Administration.

Canada-based Bausch received tentative approval for Bryhali from the FDA in October 2018 to treat plaque psoriasis in adults.

Plaque psoriasis is the most common form of psoriasis, in which the skin is red and covered with silvery scales or patches.

As part of the settlement, Glenmark acknowledged Bausch's patents for the lotion. Final patent expiry on Bryhali Lotion is 2031.